The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist; this LGI1 antibody will recognize only the longer form. This LGI1 antibody is predicted to be specific to LGI1 and not recognize other LGI proteins.

Abbiotec坚信与我们的科学家，客户，合作者和分销商社区建立牢固而有意义的合作伙伴关系。我们通过研究合作与社区分享我们的想法，并通过有益于生命科学界的创新和有用的产品来回馈青睐。我们欢迎有关研究或产品创意的讨论，我们将努力为此类讨论提供最有利和最机密的环境。Abbiotec利用专有技术和特殊资源开发自己的产品，以实现高质量的生产和控制。我们还从其他合作伙伴（例如个人科学家，大学外发许可部门和其他生物技术公司）获得产品和想法的许可。被许可的技术或想法被开发为商业产品，并通过我们的营销和销售网络在全球范围内销售。